30 Results for "

intravenous administration

" in MedChemExpress (MCE) Product Catalog:
Products (30)

30 Results for "intravenous administration" in MCE Product Catalog:

36
36 Publications Verification
Cat. No.: HY-15346
CAS No.: 1032568-63-0
Purity:  99.50%
Synonyms: BAY 80-6946
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
loading...
    loading...
36
36 Publications Verification
Cat. No.: HY-15346A
CAS No.: 1402152-13-9
Purity:  99.55%
Synonyms: BAY 80-6946 dihydrochloride
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15346R
CAS No.: 1032568-63-0
Synonyms: BAY 80-6946 (Standard)
Research Areas:  

Cancer

Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
loading...
    loading...
Cat. No.: HY-P4154
CAS No.: 2276787-79-0
Synonyms: ALM-488
Target:  

Fluorescent Dye

Research Areas:  

Neurological Disease Cancer

Bevonescein (ALM-488) is a fluorescein-conjugated peptide that facilitates the targeted delivery of a fluorescent moiety (5-FAM (HY-66022)) to nerves after intravenous (IV) administration. Bevonescein binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves (Ex/Em = 480/530 nm) .
loading...
    loading...
Cat. No.: HY-Y0850U3
CAS No.: 9002-89-5
Synonyms: Polyvinyl alcohol (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization); Poly(Ethenol) (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization)
PVA (Polyvinyl alcohol) (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is a water-soluble, biodegradable, biocompatible and non-immunogenic polymer. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) causes no irritation to rabbit eyes, no skin sensitization in guinea pigs, promotes the proliferation of human skin keratinocytes, and reduces the loss of corneal endothelial cells. The LD50 of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) in rats and dogs is greater than 10 g/kg. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is hardly absorbed by the digestive system, causes no adverse effects upon long-term oral administration, and shows no mutagenicity or carcinogenicity. However, repeated intravenous or portal vein injection of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) may induce pathological changes such as glomerular lesions, anemia, hypertension or liver fibrosis in rats or dogs. Crosslinked nanofibers prepared by modifying PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) can be used in studies related to wound dressings and other applications .
loading...
    loading...
Cat. No.: HY-N10225
CAS No.: 71950-66-8
Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
loading...
    loading...
Cat. No.: HY-135578
CAS No.: 120020-26-0
Purity:  99.96%
Target:  

Parasite

Research Areas:  

Infection

Artelinic acid, a derivative of Artemisinin, is an antimalarial agent for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes .
loading...
    loading...
Cat. No.: HY-134160
CAS No.: 696-06-0
Purity:  99.90%
Synonyms: 5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione; 5-Fluorodihydrouracil
Research Areas:  

Cancer

5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.
loading...
    loading...
Cat. No.: HY-116763
CAS No.: 443919-96-8
Target:  

COX LOX-1

COX-2/5-LOX-IN-4 (Compound 1) is a dual inhibitor that acts on both COX-2 and 5-LOX, with IC50 values of 0.05 μM for COX-2 and 0.003 μM for 5-LOX. By inhibiting the arachidonic acid metabolism pathway, COX-2/5-LOX-IN-4 reduces the production of prostaglandins and leukotrienes, alleviating inflammatory responses. In a rat ear edema model, intravenous administration (0.01 and 0.1 mg/kg) reduced edema by 41% and 44%, respectively, demonstrating significant anti-inflammatory effects. COX-2/5-LOX-IN-4 shows promise for studying the mechanisms of inflammatory diseases .
loading...
    loading...
Cat. No.: HY-105215
CAS No.: 138449-07-7
Target:  

Neurokinin Receptor

Research Areas:  

Inflammation/Immunology

FK888 is a potent, selective, and high affinity dipeptide NK1 receptor antagonist. FK888 displaces [3H]-SP binding with a Ki value of 0.69 nM and 0.45 microM. FK888 also inhibits SP-induced airway oedema in guinea-pig after both intravenous and oral administration .
loading...
    loading...
Cat. No.: HY-134160S
CAS No.: 1189492-99-6
Synonyms: 5-DHFU-13C,15N2; 5-Fluorodihydropyrimidine-2,4-dione-13C,15N2; 5-Fluorodihydrouracil-13C,15N2
5,6-Dihydro-5-Fluorouracil- 13C, 15N2 (5-DHFU- 13C, 15N2) is the 13C- and 15N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.
loading...
    loading...
Cat. No.: HY-B1657
CAS No.: 93390-81-9
Target:  

Drug Intermediate

Research Areas:  

Neurological Disease

Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .
loading...
    loading...
Cat. No.: HY-N6910
CAS No.: 82508-35-8
Pseudolaric Acid C2, a diterpenoid isolated from Pseudolarix kaempferi, is identified as the specific metabolite of Pseudolaric acid B in plasma, urine, bile and feces after both oral and intravenous administration to rats .
loading...
    loading...
Cat. No.: HY-159640
Target:  

Parasite

Research Areas:  

Infection

NVP-FVP954 is a fast-acting antimalarial agent with potential for severe malaria. FVP954 has a high barrier to resistance, long half-life, and high solubility, making it suitable for intravenous administration .
loading...
    loading...
Cat. No.: HY-105919
CAS No.: 120819-70-7
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
loading...
    loading...
Cat. No.: HY-100435
CAS No.: 790704-50-6
Synonyms: MCB-3837; DNV3837
Target:  

Bacterial

Research Areas:  

Infection

Oxaquin (MCB-3837) is a injectable proagent that is rapidly converted to the active substance MCB3681 in vivo following intravenous (i.v.) administration, active against Gram-positive bacterial species. Oxaquin (MCB-3837) itself has no antimicrobial effects .
loading...
    loading...
Cat. No.: HY-14795
CAS No.: 180694-97-7
Synonyms: ZT-1
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

Mimopezil (ZT-1) is an cholinesterase (ChE) inhibitor that rapidly degrades into the active metabolite Huperzine A (HY-17388) in water or aqueous organic solvents. After oral administration, Mimopezil is rapidly absorbed but has low bioavailability (0.37%) in rats. However, after metabolism, it is converted into Huperzine A, which accumulates in the blood and exhibits strong activity. Following intravenous administration, Mimopezil reaches higher blood concentrations and is also rapidly metabolized into Huperzine A .
loading...
    loading...
Cat. No.: HY-19454
CAS No.: 193272-70-7
Target:  

GHSR

Research Areas:  

Cardiovascular Disease

CP-464709 is a Ghrelin receptor agonist that can penetrate the blood-brain barrier. CP-464709 causes an increase in blood pressure by activating pre sympathetic neurons in the spinal cord. CP-464709 causes biphasic blood pressure response when administered intravenously, while intrathecal administration only causes pressor. CP-464709 can be used for research on cardiovascular conditions .
loading...
    loading...
Cat. No.: HY-118185
CAS No.: 115766-42-2
Target:  

Renin

Research Areas:  

Others

SQ 31844 is a novel renin inhibitor belonging to the imidazolidinol class. This compound, which contains an imidazole ring in its active site binding group, has potent in vitro inhibition of primate renin, but not rat, pig, or dog renin. In conscious, sodium-deprived cynomolgus monkeys, both compounds produced dose-related inhibition of plasma renin activity (PRA) over a dose range of 0.001 to 1.0 μmol/kg, administered intravenously, with complete inhibition observed at the highest dose. However, a reduction in blood pressure was only observed when 10 μmol/kg was administered intravenously or by infusion. In sodium-replete monkeys, SQ 30774 inhibited the increase in arterial blood pressure and PRA following administration of exogenous monkey renin. When the compounds were administered orally at 50 μmol/kg, only SQ 31844 significantly inhibited PRA (80%). In summary, the imidazolidinol renin inhibitors have potent inhibitory effects on renin in vitro and inhibit PRA and reduce arterial blood pressure in vivo.
loading...
    loading...
Cat. No.: HY-15074
CAS No.: 245063-59-6
Synonyms: NS-1209
Target:  

iGluR

Research Areas:  

Neurological Disease

SPD-502 is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 may be promising for studying neurodegenerative conditions associated with glutamate excitotoxicity .
loading...
    loading...